Q-linea AB (OSTO:QLINEA) Total Liabilities: kr40.09 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:QLINEA Q-linea AB OSTO:QLINEA
65 GF Score
Price kr17.05
GF Value kr19.70
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Q-linea AB Total Liabilities?

Q-linea AB OSTO:QLINEA -0.29% 65 Total Liabilities is kr40.09 Mil as of Jun. 2026. GuruFocus rates OSTO:QLINEA with a GF Score™ of 65/100 and a GF Value™ of kr19.70 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Q-linea AB's Total Liabilities for the quarter that ended in Jun. 2026 was kr40.09 Mil.

Q-linea AB's quarterly Total Liabilities declined from Dec. 2025 (kr31.67 Mil) to Mar. 2026 (kr29.06 Mil) but then increased from Mar. 2026 (kr29.06 Mil) to Jun. 2026 (kr40.09 Mil).

Q-linea AB's annual Total Liabilities increased from Dec. 2023 (kr42.34 Mil) to Dec. 2024 (kr175.45 Mil) but then declined from Dec. 2024 (kr175.45 Mil) to Dec. 2025 (kr31.67 Mil).

Q-linea AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Q-linea AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-linea AB Total Liabilities Chart

Q-linea AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.01 66.73 42.34 175.45 31.67

Q-linea AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.55 67.93 31.67 29.06 40.09
OSTO:QLINEA
65GF Score
Q-linea AB OSTO:QLINEA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-linea AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Q-linea AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=29.795+(1.87+-2.6645352591004E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=31.67

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=369.668-338.003
=31.67

Q-linea AB's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.244+(9.433+28.413
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=40.09

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=314.773-274.683
=40.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr40.09 Mil mean?
Q-linea AB (OSTO:QLINEA) has a Total Liabilities of kr40.09 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Q-linea AB and its competitors.
Is Q-linea AB's Total Liabilities too high?
Q-linea AB's current Total Liabilities is kr40.09 Mil. Overall, Q-linea AB has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Total Liabilities compare to ABT and SYK?
Q-linea AB's Total Liabilities of kr40.09 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Q-linea AB and its competitors. Q-linea AB's current Total Liabilities is kr40.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Based on GuruFocus' analysis, Q-linea AB (OSTO:QLINEA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr19.70, compared to a current price of kr17.05 — trading 13.5% below its estimated fair value. The current Total Liabilities is kr40.09 Mil. Q-linea AB's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Q-linea AB (OSTO:QLINEA), the current Total Liabilities is kr40.09 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Q-linea AB (OSTO:QLINEA) Overvalued in 2026?

Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued. The current stock price of kr17.05 is trading 13.5% below its estimated GF Value™ of kr19.70. GuruFocus considers Q-linea AB to be Modestly Undervalued.

Key valuation signals for OSTO:QLINEA:

  • Total Liabilities: kr40.09 Mil
  • GF Value™: kr19.70 vs. price of kr17.05 (13.5% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the OSTO:QLINEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Q-linea AB Business Description

Other Exchanges 3F80:Germany
Address Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
65GF Score

Get the complete analysis for OSTO:QLINEA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr17.05
Price
kr19.70
GF Value